NASDAQ: GILDGilead Sciences Inc Stock Ownership
Insider buying vs selling
Have Gilead Sciences Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Brett A. Pletcher | EVPCorp Affairs & Gen Counsel | 2021-03-11 | 1,486 | $63.36 | $94.15kSell |
| Merdad Parsey | Chief Medical Officer | 2021-03-10 | 1,639 | $63.91 | $104.75kSell |
| Johanna Mercier | Chief Commercial Officer | 2021-03-10 | 1,435 | $63.91 | $91.71kSell |
| Diane E. Wilfong | SVP Controller & CAO | 2021-03-10 | 609 | $63.91 | $38.92kSell |
| Andrew D. Dickinson | Chief Financial Officer | 2021-03-10 | 1,771 | $63.91 | $113.18kSell |
| Brett A. Pletcher | EVPCorp Affairs & Gen Counsel | 2021-03-10 | 1,107 | $63.91 | $70.75kSell |
| Daniel Patrick Oday | Chairman & CEO | 2021-03-10 | 5,123 | $63.91 | $327.41kSell |
| Daniel Patrick Oday | Chairman & CEO | 2021-03-10 | 5,123 | $63.91 | $327.41kSell |
| Daniel Patrick Oday | Chairman & CEO | 2021-03-01 | 24,620 | $62.46 | $1.54MSell |
| Andrew D. Dickinson | Chief Financial Officer | 2021-02-15 | 364 | $56.86 | $20.70kBuy |
GILD insiders have sold more GILD shares than they have bought in the last year
Ownership
GILD Shareholders
What type of owners hold Gilead Sciences Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Capital Research Global Investors | 9.71% | 121,672,399 | $7.87B | Institution |
| Blackrock Inc | 8.87% | 111,183,334 | $7.19B | Institution |
| Vanguard Group Inc | 8.20% | 102,787,017 | $6.65B | Institution |
| State Street Corp | 4.40% | 55,206,559 | $3.57B | Institution |
| Capital International Investors | 3.71% | 46,548,996 | $3.01B | Institution |
| Capital World Investors | 3.07% | 38,534,588 | $2.49B | Institution |
| Geode Capital Management LLC | 1.60% | 20,078,920 | $1.30B | Institution |
| Dodge Cox | 1.36% | 17,107,888 | $1.11B | Institution |
| Northern Trust Corp | 1.22% | 15,243,829 | $985.67M | Institution |
| Bank Of New York Mellon Corp | 1.10% | 13,806,532 | $892.73M | Institution |
Gilead Sciences Stock Ownership FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.